Identification of Novel Mutations Associated with Bedaquiline Resistance in Mycobacterium Marinum
نویسندگان
چکیده
Objective: Because infections caused by nontuberculous mycobacteria (NTM) are rapidly increasing globally, a need exists for developing novel antibiotics and discovering the mechanism of resistance. This research was aimed at understanding bedaquiline resistance in model NTM species Mycobacterium marinum ( M. ). Methods: The M strain subjected to mutant selection with different concentrations BDQ. After three rounds evolution, 58 BDQ-resistant mutants were isolated WGS. results confirmed through PCR Sanger sequencing. Results: We identified seven genetic mutations among these mutants. highest drug (6–10× MIC) associated mutation AtpB, primary biochemical target BDQ Mtb. Numerous insertions mapped gene MMAR_1007 (46/58), which encodes homolog Rv0678 (MmpR) More than 93% (54/58) contained single (G563A) MMAR_4049 , integral membrane protein YrbE3A-1. Conclusion: Both target-based efflux-based actions contribute marinum. Our findings may aid potent anti-NTM (BDQ-based) regimens diagnostic assays detection .
منابع مشابه
Identification of novel mutations associated with clofazimine resistance in Mycobacterium tuberculosis.
OBJECTIVES Although clofazimine has been traditionally used to treat leprosy, there is recent interest in using clofazimine for the treatment of MDR-TB and drug-susceptible TB. However, the mechanisms of resistance to clofazimine are poorly understood. Here, we investigated the molecular basis of clofazimine resistance using resistant mutants isolated in vitro. METHODS We isolated 96 mutants ...
متن کاملIdentification of novel mutations associated with cycloserine resistance in Mycobacterium tuberculosis.
Objectives d-Cycloserine is an important second-line drug used to treat MDR- and XDR-TB. However, the mechanisms of resistance to d-cycloserine are not well understood. Here we investigated the molecular basis of d-cycloserine resistance using in vitro-isolated resistant mutants. Methods Mycobacterium tuberculosis H37Rv was subjected to mutant selection on 7H11 agar plates containing varying ...
متن کاملAcquired Resistance of Mycobacterium tuberculosis to Bedaquiline
Bedaquiline (BDQ), an ATP synthase inhibitor, is the first drug to be approved for treatment of multi-drug resistant tuberculosis in decades. In vitro resistance to BDQ was previously shown to be due to target-based mutations. Here we report that non-target based resistance to BDQ, and cross-resistance to clofazimine (CFZ), is due to mutations in Rv0678, a transcriptional repressor of the genes...
متن کاملRifampin resistance in Mycobacterium kansasii is associated with rpoB mutations.
Rifampin is the most potent drug used in the treatment of disease due to Mycobacterium kansasii. A 69-bp fragment of rpoB, the gene that encodes the beta subunit of the bacterial RNA polymerase, was sequenced and found to be identical in five rifampin-susceptible clinical isolates of M. kansasii. This sequence showed 87% homology with the Mycobacterium tuberculosis gene, with an identical deduc...
متن کاملA mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment.
tuberculosis prevention, care and control after 2015. Geneva, WHO, 2014. 13 World Health Organization. Definitions and reporting framework for tuberculosis – 2013 revision. Geneva, WHO, 2013. 14 Van Deun A, Maug AK, Bola V, et al. Rifampicin drug resistance tests for tuberculosis: challenging the gold standard. J Clin Microbiol 2013; 51: 2633–2640. 15 Salje H, Andrews JR, Deo S, et al. The impo...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Zoonoses
سال: 2023
ISSN: ['2737-7474', '2737-7466']
DOI: https://doi.org/10.15212/zoonoses-2022-0042